|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 746.80 USD | +2.84% |
|
+3.32% | +4.84% |
| 10/12 | Regeneron Pharmaceuticals, Inc. - Special Call | |
| 10/12 | Wells Fargo Adjusts PT on Regeneron Pharmaceuticals to $745 From $700, Maintains Equalweight Rating | MT |
| Capitalization | 7.45TCr 6.34TCr 5.92TCr 5.55TCr 10TCr 6,72100Cr 11TCr 69TCr 27TCr 3,17500Cr 28TCr 27TCr 11,56800Cr | P/E ratio 2025 * |
17.8x | P/E ratio 2026 * | 18.9x |
|---|---|---|---|---|---|
| Enterprise value | 6.79TCr 5.78TCr 5.4TCr 5.06TCr 9.36TCr 6,12800Cr 10TCr 63TCr 24TCr 2,89500Cr 25TCr 25TCr 10,54800Cr | EV / Sales 2025 * |
4.78x | EV / Sales 2026 * | 4.36x |
| Free-Float |
77.36% | Yield 2025 * |
0.51% | Yield 2026 * | 0.54% |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | +2.84% | ||
| 1 week | +3.32% | ||
| Current month | -4.28% | ||
| 1 month | +10.71% | ||
| 3 months | +31.43% | ||
| 6 months | +44.00% | ||
| Current year | +4.84% |
| 1 week | 691.86 |  | 753.61 |
| 1 month | 672.67 | | 790.98 |
| Current year | 476.49 | | 790.98 |
| 1 year | 476.49 | | 790.98 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 441 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 65 | 01/01/2001 | |
| Chief Executive Officer | 72 | 08/01/1988 | |
| Director of Finance/CFO | 54 | 05/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 72 | 09/06/2023 | |
Michael Brown
BRD | Director/Board Member | 84 | 01/06/1991 |
Joseph Goldstein
BRD | Director/Board Member | 84 | 01/06/1991 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.84% | +3.32% | -3.39% | +0.58% | 7.45TCr | |
| -1.55% | -1.91% | -36.59% | -40.09% | 5.82TCr | |
| -0.62% | +0.38% | +33.43% | +235.89% | 5.36TCr | |
| +0.24% | +66.90% | +66.90% | +66.90% | 5.24TCr | |
| -2.84% | -5.21% | +9.55% | -40.64% | 2.6TCr | |
| +0.98% | -4.34% | +32.57% | +16.68% | 1.87TCr | |
| +0.18% | -8.88% | +119.27% | +159.38% | 1.84TCr | |
| -0.66% | -13.12% | +42.61% | +1,004.75% | 1.66TCr | |
| -0.04% | -.--% | +58.67% | +154.72% | 1.4TCr | |
| +1.88% | -0.93% | +155.57% | +711.23% | 1.4TCr | |
| Average | +0.04% | -1.70% | +47.86% | +226.94% | 3.47TCr | |
| Weighted average by Cap. | +0.18% | -0.63% | +27.92% | +129.47% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1.42TCr 1.21TCr 1.13TCr 1.06TCr 1.96TCr 1,28100Cr 2.13TCr 13TCr 5.11TCr 61TCr 5.33TCr 5.22TCr 2,20500Cr | 1.51TCr 1.29TCr 1.2TCr 1.13TCr 2.08TCr 1,36300Cr 2.27TCr 14TCr 5.43TCr 64TCr 5.67TCr 5.55TCr 2,34500Cr |
| Net income | 413.89Cr 352.14Cr 328.77Cr 308.44Cr 570.32Cr 37TCr 620.92Cr 3.83TCr 1.49TCr 18TCr 1.55TCr 1.52TCr 64TCr | 403.13Cr 342.98Cr 320.22Cr 300.42Cr 555.49Cr 36TCr 604.77Cr 3.73TCr 1.45TCr 17TCr 1.51TCr 1.48TCr 63TCr |
| Net Debt | -657.05Cr -559.02Cr -521.91Cr -489.65Cr -905.38Cr -59TCr -985.7Cr -6.08TCr -2.36TCr -28TCr -2.47TCr -2.41TCr -1,02000Cr | -863.41Cr -734.59Cr -685.83Cr -643.44Cr -1.19TCr -78TCr -1.3TCr -7.99TCr -3.1TCr -37TCr -3.24TCr -3.17TCr -1,34100Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/25/12 | 746.80 $ | +2.84% | 11,46,214 |
| 10/25/10 | 726.21 $ | +4.86% | 13,16,662 |
| 09/25/09 | 692.58 $ | -1.52% | 6,04,535 |
| 08/25/08 | 703.26 $ | -2.10% | 10,05,953 |
| 05/25/05 | 718.36 $ | -0.61% | 7,98,452 |
Delayed Quote Nasdaq, December 12, 2025 at 02:30 am IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition